On Invalid Date, Celldex Therapeutics (NASDAQ: CLDX) reported Q4 2023 earnings per share (EPS) of -$0.84, up 47.37% year over year. Total Celldex Therapeutics earnings for the quarter were -$43.31 million. In the same quarter last year, Celldex Therapeutics's earnings per share (EPS) was -$0.57.
As of Q2 2024, Celldex Therapeutics's earnings has grown year over year. Celldex Therapeutics's earnings in the past year totalled -$141.43 million.
What is CLDX's earnings date?
Celldex Therapeutics's earnings date is Invalid Date. Add CLDX to your watchlist to be reminded of CLDX's next earnings announcement.
What was CLDX's revenue last quarter?
On Invalid Date, Celldex Therapeutics (NASDAQ: CLDX) reported Q4 2023 revenue of $4.13 million up 156.11% year over year. In the same quarter last year, Celldex Therapeutics's revenue was $1.61 million.
What was CLDX's revenue growth in the past year?
As of Q2 2024, Celldex Therapeutics's revenue has grown 192.02% year over year. This is 46.8 percentage points higher than the US Biotechnology industry revenue growth rate of 145.22%. Celldex Therapeutics's revenue in the past year totalled $6.88 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.